Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Alexandr, Poprach"'
Autor:
Radek Lakomý, Martina Lojová, Lenka Souckova, Ludmila Hynkova, Katerina Polachova, Jiri Vasina, Regina Demlová, Alexandr Poprach, Jiri Sana, Tomas Prochazka, Martin Smrcka, Pavel Fadrus, Radim Jancalek, Iveta Selingerova, Renata Belanova, Pavel Slampa, Petr Pospisil, Tomas Kazda
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If po
Externí odkaz:
https://doaj.org/article/bebe9980a0a64643b438dbf725e4abd3
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 537-542 (2024)
Introduction: Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzal
Externí odkaz:
https://doaj.org/article/860706c596654c838ad4939e72dde932
Autor:
Igor Richter, Alexandr Poprach, Anezka Zemankova, Tomas Buchler, Jiri Bartos, Vladimir Samal, Hana Studentova, Aneta Rozsypalova, Josef Dvorak, Ondrej Brom, Bohuslav Melichar
Publikováno v:
Biomedical Papers, Vol 166, Iss 1, Pp 97-104 (2022)
Aim. The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and Methods. Cabozantinib was administered in dose 60 mg/day, a subset of p
Externí odkaz:
https://doaj.org/article/15cacfbb56434393aa47bcaf504f7acd
Autor:
Milos Holanek, Iveta Selingerova, Pavel Fabian, Oldrich Coufal, Ondrej Zapletal, Katarina Petrakova, Tomas Kazda, Roman Hrstka, Alexandr Poprach, Maria Zvarikova, Ondrej Bilek, Marek Svoboda
Publikováno v:
Diagnostics, Vol 12, Iss 7, p 1740 (2022)
A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved pathologic complete remission. This single-institutional retrospective study of 767 consecut
Externí odkaz:
https://doaj.org/article/683bdd4ed2e2407987165083b0d972a6
Autor:
Radek Lakomy, Tomas Kazda, Iveta Selingerova, Alexandr Poprach, Petr Pospisil, Renata Belanova, Pavel Fadrus, Vaclav Vybihal, Martin Smrcka, Radim Jancalek, Ludmila Hynkova, Katarina Muckova, Michal Hendrych, Jiri Sana, Ondrej Slaby, Pavel Slampa
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblast
Externí odkaz:
https://doaj.org/article/1d0758fd945243c3bb797cdae45d2383
Autor:
Radek Lakomy, Alexandr Poprach, Zbynek Bortlicek, Bohuslav Melichar, Renata Chloupkova, Rostislav Vyzula, Milada Zemanova, Katerina Kopeckova, Marek Svoboda, Ondrej Slaby, Igor Kiss, Hana Studentova, Jaroslav Juracek, Ondrej Fiala, Jindrich Kopecky, Jindrich Finek, Ladislav Dusek, Karel Hejduk, Tomas Buchler
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment str
Externí odkaz:
https://doaj.org/article/0a8555e1bc4d4de2ae22bfbdd71ada34
Autor:
Pavla Bouchalova, Jindrich Beranek, Petr Lapcik, David Potesil, Jan Podhorec, Alexandr Poprach, Pavel Bouchal
Publikováno v:
Biomedicines, Vol 9, Iss 9, p 1145 (2021)
Renal cell carcinoma (RCC) represents about 2–3% of all cancers with over 400,000 new cases per year. Sunitinib, a vascular endothelial growth factor tyrosine kinase receptor inhibitor, has been used mainly for first-line treatment of metastatic cl
Externí odkaz:
https://doaj.org/article/5f4a174c514e4526ab6fe5e567ad82ae
Publikováno v:
Onkologie. 16:130-133
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de582d2b8d634e1c796dbdf815fc1761
https://doi.org/10.36290/xon.2022.026
https://doi.org/10.36290/xon.2022.026
Autor:
Alexandr Poprach, Anezka Zemankova, Igor Richter, Bohuslav Melichar, Hana Študentová, Aneta Rozsypalova, Tomas Buchler, Vladimir Samal, Josef Dvorak, Ondrej Brom, Jiri Bartos
Publikováno v:
Biomedical Papers. 166:97-104
Aim The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and methods Cabozantinib was administered in dose 60 mg/day, a subset of pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c642cdf78a2446e03d6a284085472c25
https://doi.org/10.5507/bp.2020.055
https://doi.org/10.5507/bp.2020.055
Autor:
Julia Bohosova, Katerina Kozelkova, Dagmar Al Tukmachi, Karolina Trachtova, Ondrej Naar, Michaela Ruckova, Eva Kolarikova, Michal Stanik, Alexandr Poprach, Ondrej Slaby
Publikováno v:
Journal of cancer research and clinical oncology
Purpose Renal cell carcinoma belongs among the deadliest malignancies despite great progress in therapy and accessibility of primary care. One of the main unmet medical needs remains the possibility of early diagnosis before the tumor dissemination a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97ad83246797095f59bdee51094282a5
https://is.muni.cz/publication/2293479
https://is.muni.cz/publication/2293479
